{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:21Z","timestamp":1740107001612,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00520-022-07440-5","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T04:31:13Z","timestamp":1668141073000},"page":"9833-9840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial"],"prefix":"10.1007","volume":"30","author":[{"given":"Reza","family":"Ershadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matin","family":"Vahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein Kazemi","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Ebrahimpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad Sarbaz","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-4959","authenticated-orcid":false,"given":"Shahab","family":"Rafieian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"7440_CR1","doi-asserted-by":"crossref","unstructured":"Beaudoin S, Gonzalez A (2018) Evaluation of the patient with pleural effusion. CMAJ 190(10):E291\u2013E295","DOI":"10.1503\/cmaj.170420"},{"key":"7440_CR2","doi-asserted-by":"crossref","unstructured":"Bender B, Murthy V, Chamberlain RS (2016) The changing management of chylothorax in the modern era. Eur J Cardiothorac Surg 49(1):18\u201324","DOI":"10.1093\/ejcts\/ezv041"},{"key":"7440_CR3","doi-asserted-by":"crossref","unstructured":"Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M et al (2019) ERS\/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg 55(1):116\u2013132","DOI":"10.1093\/ejcts\/ezy258"},{"key":"7440_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1747-0803.2010.00464.x","volume":"5","author":"L Caverly","year":"2010","unstructured":"Caverly L, Rausch CM, da Cruz E, Kaufman J (2010) Octreotide treatment of chylothorax in pediatric patients following cardiothoracic surgery. Congenit Heart Dis 5:573\u2013578","journal-title":"Congenit Heart Dis"},{"key":"7440_CR5","doi-asserted-by":"crossref","unstructured":"Chen Y, Mathy NW, Lu H (2018) The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non\u2011small cell lung cancer. Mol Med Rep 17(6):8019\u20138030","DOI":"10.3892\/mmr.2018.8922"},{"key":"7440_CR6","doi-asserted-by":"crossref","unstructured":"Helin RD, Angeles STV, Bhat R (2006) Octreotide therapy for chylothorax in infants and children: a brief review. Pediatr Crit Care Med 7(6):576\u2013579","DOI":"10.1097\/01.PCC.0000235256.00265.C8"},{"key":"7440_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000337246","volume":"82","author":"A Jatoi","year":"2012","unstructured":"Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC (2012) A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology 82:315\u2013320","journal-title":"Oncology"},{"key":"7440_CR8","doi-asserted-by":"crossref","unstructured":"Kambayashi T, Nakatsukasa H, Motoi M, Kato N (2012) Investigation of the utility of octreotide for malignant ascites. Palliat Care Res 7(1):314\u2013316","DOI":"10.2512\/jspm.7.314"},{"key":"7440_CR9","unstructured":"Kilic D, Sahin E, Gulcan O, Bolat B, Turkoz R, Hatipoglu A (2005) Octreotide for treating chylothorax after cardiac surgery. Tex Heart Inst J 32(3):437\u2013439"},{"key":"7440_CR10","doi-asserted-by":"crossref","unstructured":"Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I (2017) Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res 9(10):229\u2013241","DOI":"10.2147\/CMAR.S95663"},{"key":"7440_CR11","doi-asserted-by":"crossref","unstructured":"Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT (2016) Malignant pleural effusion: from bench to bedside. Eur Respir Rev 25(140):189\u2013198","DOI":"10.1183\/16000617.0019-2016"},{"key":"7440_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s00134-006-0114-9","volume":"32","author":"CC Roehr","year":"2006","unstructured":"Roehr CC, Jung A, Proquitt\u00e9 H, Blankenstein O, Hammer H, Lakhoo K, Wauer RR (2006) Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med 32:650\u2013657","journal-title":"Intensive Care Med"},{"key":"7440_CR13","first-page":"e151","volume":"101","author":"D Shah","year":"1992","unstructured":"Shah D (1992) Sinn JK (2012) Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series Acta paediatrica (Oslo. Norway 101:e151-155","journal-title":"Norway"},{"key":"7440_CR14","unstructured":"Sharkey AJ, Rao JN (2012) The successful use of octreotide in the treatment of traumatic chylothorax. Tex Heart Inst J 39(3):428"},{"key":"7440_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","volume":"186","author":"GT Stathopoulos","year":"2012","unstructured":"Stathopoulos GT, Kalomenidis I (2012) Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 186:487\u2013492","journal-title":"Am J Respir Crit Care Med"},{"key":"7440_CR16","first-page":"31","volume":"3","author":"J Stephens","year":"2010","unstructured":"Stephens J, Carpiuc KT, Botteman M (2010) The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 3:31\u201336","journal-title":"Int J Gen Med"},{"issue":"1\u201310","key":"7440_CR17","first-page":"v","volume":"23","author":"NG Yalcin","year":"2013","unstructured":"Yalcin NG, Choong CK, Eizenberg N (2013) Anatomy and pathophysiology of the pleura and pleural space. Thorac Cardiovasc Surg 23(1\u201310):v","journal-title":"Thorac Cardiovasc Surg"},{"key":"7440_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.athoracsur.2013.05.058","volume":"96","author":"J Yeh","year":"2013","unstructured":"Yeh J, Brown ER, Kellogg KA, Donohue JE, Yu S, Gaies MG, Fifer CG, Hirsch JC, Aiyagari R (2013) Utility of a clinical practice guideline in treatment of chylothorax in the postoperative congenital heart patient. Ann Thorac Surg 96:930\u2013936","journal-title":"Ann Thorac Surg"},{"key":"7440_CR19","doi-asserted-by":"publisher","first-page":"e7594","DOI":"10.1097\/MD.0000000000007594","volume":"96","author":"R Yin","year":"2017","unstructured":"Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, Chen C, Cao Y (2017) Effects of somatostatin\/octreotide treatment in neonates with congenital chylothorax. Medicine (Baltimore) 96:e7594\u2013e7594","journal-title":"Medicine (Baltimore)"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07440-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:30:57Z","timestamp":1669901457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7440"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07440-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethics committee of Tehran University of Medical Sciences approved the study with the number IR.TUMS.IKCH.REC.1399.498.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}